Phapros Tbk PT (JK:PEHA) — Market Cap & Net Worth
Market Cap & Net Worth: Phapros Tbk PT (PEHA)
Phapros Tbk PT (JK:PEHA) has a market capitalization of $14.67 Million (Rp250.32 Billion) as of May 3, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #25910 globally and #582 in its home market, demonstrating a 1.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Phapros Tbk PT's stock price Rp298.00 by its total outstanding shares 840000000 (840.00 Million). Analyse PEHA cash generation efficiency to see how efficiently the company converts income to cash.
Phapros Tbk PT Market Cap History: 2018 to 2026
Phapros Tbk PT's market capitalization history from 2018 to 2026. Data shows change from $118.09 Million to $14.67 Million (-20.01% CAGR).
Index Memberships
Phapros Tbk PT is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Jakarta Stock Exchange Composite Index
JKSE
|
$540.85 Billion | 0.00% | #569 of 864 |
Weight: Phapros Tbk PT's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Phapros Tbk PT Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Phapros Tbk PT's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Phapros Tbk PT's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $118.09 Million | $1.02 Trillion | $132.31 Billion | 0.00x | 0.00x |
| 2019 | $47.17 Million | $1.11 Trillion | $102.03 Billion | 0.00x | 0.00x |
| 2020 | $79.58 Million | $980.56 Billion | $48.49 Billion | 0.00x | 0.00x |
| 2021 | $52.90 Million | $1.05 Trillion | $11.07 Billion | 0.00x | 0.00x |
| 2022 | $33.05 Million | $1.17 Trillion | $28.07 Billion | 0.00x | 0.00x |
| 2023 | $31.50 Million | $1.01 Trillion | $5.96 Billion | 0.00x | 0.01x |
| 2024 | $15.95 Million | $744.69 Billion | -$285.07 Billion | 0.00x | N/A |
Competitor Companies of PEHA by Market Capitalization
Companies near Phapros Tbk PT in the global market cap rankings as of May 3, 2026.
Key companies related to Phapros Tbk PT by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Phapros Tbk PT Historical Marketcap From 2018 to 2026
Between 2018 and today, Phapros Tbk PT's market cap moved from $118.09 Million to $ 14.67 Million, with a yearly change of -20.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp14.67 Million | -0.67% |
| 2025 | Rp14.77 Million | -7.41% |
| 2024 | Rp15.95 Million | -49.38% |
| 2023 | Rp31.50 Million | -4.70% |
| 2022 | Rp33.05 Million | -37.52% |
| 2021 | Rp52.90 Million | -33.52% |
| 2020 | Rp79.58 Million | +68.71% |
| 2019 | Rp47.17 Million | -60.06% |
| 2018 | Rp118.09 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Phapros Tbk PT was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.67 Million USD |
| MoneyControl | $14.67 Million USD |
| MarketWatch | $14.67 Million USD |
| marketcap.company | $14.67 Million USD |
| Reuters | $14.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, X-Gra, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also pr… Read more